The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.
Machine Learning Approach Finds Several Severity-Associated Factors in Atopic Dermatitis
Findings of a machine learning-based deep phenotyping approach found a myriad of factors associated with severe disease in atopic dermatitis, including age between 12 and 21 years or older than 52 years, lack of physical activity, and incidence of alopecia areata.
Dr Jonathan Silverberg on Potential Benefits, Challenges of JAK Inhibitor Use in Atopic Dermatitis
Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences, explains efficacy and safety implications of JAK inhibitor use for atopic dermatitis.
Flu Vaccine May Decrease Asthma Risk in Patients With Atopic Dermatitis
Adults with atopic dermatitis were shown to be at lower risk of developing asthma if they were vaccinated against influenza, particularly those who adhered to yearly shots.
Dr Jonathan Silverberg Explains JAK/STAT Pathway Involvement in Atopic Dermatitis
Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences, discusses the involvement of the JAK/STAT pathway in the pathogenesis of atopic dermatitis.
Children With Atopic Dermatitis More Prone to Depression, Internalizing Behaviors
Children with severe atopic dermatitis were shown to be at nearly 2-fold greater risk of both depression and internalizing behaviors, with mild disease also associated with internalizing behaviors in those as young as 4 years of age.
Prenatal Exposure to Metals May Increase Risk of Atopic Dermatitis in Children
Prenatal exposure to inorganic arsenic and coexposure to inorganic arsenic and cadmium was found to increase risk of atopic dermatitis by up to 2.42-fold in young Taiwanese children.
Ruxolitinib Cream Approved for Short-term Treatment of Atopic Dermatitis
Ruxolitinib cream, to be sold under the name Opzelura, is the first topical Janus kinase inhibitor cream for the treatment of atopic dermatitis.
ICER Review of AD Therapies Narrowly Supports JAK Inhibitors, Depending on Safety
A review of therapies for atopic dermatitis (AD) found adequate net health benefit for new treatments. However, safety remains a concern for the Janus kinase (JAK) inhibitors.
Increased Mortality Seen Among Patients With Concomitant AD, Asthma
Researchers assess mortality rates among those with just asthma, just atopic dermatitis, and individuals with both conditions in Denmark.
Evaluating Dupilumab for Placement in a Value-Based Health Plan
Dupilumab is effective for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, but a recent presentation noted the payer challenge in placing the biologic in an optimal tier.
Retrospective Study Examines Dupilumab Performance in Asian Youth Population
Patients had atopic dermatitis for nearly 10 years before starting the biologic therapy.
Maternal History of Asthma Drives Risk of Atopic Dermatitis for Their Children
Children who were born to women with a history of asthma had a 45% increased risk of being diagnosed with atopic dermatitis/eczema up to age 8 years.
Patient Evaluation Scarce Among Dermatologists in France Treating Atopic Dermatitis
A survey in France found that systemic medications are used by only half of dermatologists in treating atopic dermatitis, with methotrexate used more than cyclosporine.
No Link Found Between Nutrition, Risk of Atopic Dermatitis in Children
There is no consistent evidence showing clear benefit of various nutritional factors on the risk of atopic dermatitis.
Even With Mild Disease, Children With Atopic Dermatitis Have Comorbidities
Despite the level of disease severity of atopic dermatitis, children with the condition usually have at least 1 other inflammatory or atopic comorbidity, according to new study results.
Dr Matthew J. Zirwas Discusses Step Therapy in Patients With Atopic Dermatitis
Ohio dermatologist Matthew J. Zirwas, MD, offers his view on what step therapy would look like in patients with atopic dermatitis.
Dupilumab Is Safe, Effective Among Elderly Patients With AD
A new study of dupilumab indicates that the drug is a safe and effective treatment for atopic dermatitis (AD) in elderly patients, with efficacy comparable to that seen in younger patients.
Dr Matthew J. Zirwas on Communicating About AD Treatment Persistence
Patients often ask how long they have to stay on biologic treatment for atopic dermatitis (AD), but there is a risk if therapy is stopped, says Matthew J. Zirwas, MD, a dermatologist in Ohio.
2 Clarke Drive Cranbury, NJ 08512